American Society of Clinical Oncology

Oncology & Cancer

Androgen receptor abnormality may not be associated

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). ...

Oncology & Cancer

ASCO names Cancer Advance of the Year

The American Society of Clinical Oncology (ASCO) for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic ...

page 4 from 7